Phase 3 Study of MT-0551 in Patients With Systemic Sclerosis
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The study will verify the superiority of MT-0551 to placebo at 26 weeks after treatment
initiation in systemic sclerosis (SSc) patients using the modified Rodnan Total Skin
thickness Score (mRTSS) as a measure of skin thickening. The safety and pharmacokinetics will
also be investigated.